ParVation Therapeutics, Inc.
This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find doses of the drug combination that are safe and tolerable and to look for early signs that the treatment may help control the cancer. Participants will receive the study medicines in repeating cycles and will have regular blood tests, scans, and other exams to monitor side effects and how their cancer responds.
Inclusion Criteria: * Adults (18 years and older). * Diagnosis of pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. * Cancer confirmed by tissue or cell examination (histology or cytology). * At least one measurable tumor on scans. * Good enough general health and organ function to receive study treatment, as judged by the study doctor. * Able to swallow oral medicines. * Willing to follow study visit schedule and contraception requirements. Exclusion Criteria: * Serious heart, lung, liver, or other medical problems that would make study treatment…
SNV1521 is an oral investigational anticancer drug. In this study, SNV1521 is administered at different dose levels together with the RAS inhibitor daraxonrasib in adults with locally advanced unresectable or metastatic pancreatic cancer.
Daraxonrasib is an oral targeted cancer medicine used in this study together with SNV1521. It is given once daily to help evaluate the safety and tolerability of the drug combination in people with advanced pancreatic cancer.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.